Key Takeaways
- IOI occurred in approximately 2% of injections and in about 9% of treated eyes and patients.
- All cases were mild, limited to anterior inflammation, and resolved with topical therapy without affecting visual acuity.
- IOI incidence was significantly higher with vial use than with pre-filled syringes (2.26% vs 0.21%).
Sterile intraocular inflammation (IOI) occurred more frequently with intravitreal aflibercept 8 mg in real-world use than previously reported in clinical trials, with significantly higher rates observed when injections were administered from vials compared with pre-filled syringes, according to a study.
Researchers reviewed electronic medical records from patients who received aflibercept 8 mg injections. A total of 2,631 injections were given to 453 eyes of 398 patients. IOI was observed in 41 eyes (37 patients), occurring in approximately 2% of injections and in about 9% of treated eyes and patients.
The mean time to presentation was 7.3 days after an average of 4.7 injections. All cases involved anterior chamber and/or vitreous inflammation without posterior segment involvement, and no retinal vasculitis or infiltrates were reported. Inflammation resolved with topical corticosteroids and/or nonsteroidal anti-inflammatory drugs, with no significant change in best-corrected visual acuity compared with pre-event levels.
Incidence varied significantly by formulation, with IOI occurring in 2.26% of injections using vials compared with 0.21% using pre-filled syringes (P = 0.010).
Reference
Hoffmann L, Hatz K. Lower Rates of Intraocular Inflammation with Aflibercept 8 mg Delivered via Pre-Filled Syringe Versus Vial. Ophthalmol Ther. 2026;doi: 10.1007/s40123-026-01349-6. Epub ahead of print. PMID: 41832302.
Related Content
